{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T05:19:02Z","timestamp":1734153542463,"version":"3.30.2"},"reference-count":20,"publisher":"Galenos Yayinevi","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjod"],"DOI":"10.4274\/tjod.galenos.2024.65703","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T07:18:37Z","timestamp":1733987917000},"page":"280-285","source":"Crossref","is-referenced-by-count":0,"title":["Association between serum copeptin levels and non-obese normoglycemic polycystic ovary syndrome: A case control study"],"prefix":"10.4274","volume":"21","author":[{"given":"Engin","family":"Y\u0131ld\u0131r\u0131m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00dcmit","family":"G\u00f6rkem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108:2447-69.","DOI":"10.1210\/clinem\/dgad463"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.","DOI":"10.1038\/nrdp.2016.57"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev. 2013;14:95-109.","DOI":"10.1111\/j.1467-789X.2012.01053.x"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Haddad-Filho H, Tosatti JAG, Vale FM, Gomes KB, Reis FM. Updates in diagnosing polycystic ovary syndrome-related infertility. Expert Rev Mol Diagn. 2023;23:123-132.","DOI":"10.1080\/14737159.2023.2177536"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Thessaloniki ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462-77.","DOI":"10.1093\/humrep\/dem426"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr, et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab. 2009;94:2558-64.","DOI":"10.1210\/jc.2008-2278"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Polak K, Czyzyk A, Simoncini T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 2017;40:1-8.","DOI":"10.1007\/s40618-016-0523-8"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Estienne A, Bongrani A, Reverchon M, Ram\u00e9 C, Ducluzeau PH, Froment P, et al. Involvement of novel adipokines, chemerin, visfatin, resistin and apelin in reproductive functions in normal and pathological conditions in humans and animal models. Int J Mol Sci. 2019;20:4431.","DOI":"10.3390\/ijms20184431"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Taskin MI, Bulbul E, Adali E, Hismiogullar\u0131 AA, Inceboz U. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2015189:19-23.","DOI":"10.1016\/j.ejogrb.2015.03.006"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. G\u00f6rkem \u00dc, Y\u0131ld\u0131r\u0131m E. Copeptin: A potential marker for the prediction of poor ovarian reserve in the infertile women. Turk J Obstet Gynecol. 2022;19:281-6.","DOI":"10.4274\/tjod.galenos.2022.55856"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Schill F, Timpka S, Nilsson PM, Melander O, Enh\u00f6rning S. Copeptin as a predictive marker of incident heart failure. ESC Heart Fail. 2021;8:3180-8.","DOI":"10.1002\/ehf2.13439"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Jalleh R, Torpy DJ. The emerging role of copeptin. Clin Biochem Rev. 2021;42:17-25.","DOI":"10.33176\/AACB-20-00001"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Orio F, Muscogiuri G, Nese C, Palomba S, Savastano S, Tafuri D, et al. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016;207:214-9.","DOI":"10.1016\/j.ejogrb.2016.08.026"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Karbek B, Ozbek M, Karakose M, Topaloglu O, Bozkurt NC, Cak\u0131r E, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. J Ovarian Res. 2014;7:31.","DOI":"10.1186\/1757-2215-7-31"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Rojas-Humpire R, Soriano-Moreno DR, Galindo-Yllu B, Zafra-Tanaka JH. Association between copeptin and metabolic syndrome: a systematic review. J Nutr Metab. 2022;2022:5237903.","DOI":"10.1155\/2022\/5237903"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Al\u0131 AI, Hassan WN, Alraw\u0131 S. A copeptin as a predictor marker for insulin resistance among women with polycystic ovary syndrome. Curr Womens Health Rev. 2022;18:67-72.","DOI":"10.2174\/1573404817666211208152049"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Coelho JM, D'cunha P, Sh\u0131vashankara AR. Serum copeptin as a biomarker of polycystic ovarian syndrome and its correlation with metabolic syndrome components: a cross-sectional analytical study. Journal of Clinical and Diagnostic Research. 2024;18:7.","DOI":"10.7860\/JCDR\/2024\/69942.19604"},{"key":"ref17","unstructured":"18. Popovic M. The role of interleukin-1 in the pathophysiology of polycystic ovary syndrome and regulation of copeptin [dissertation]. Basel (Switzerland): University of Basel; 2021."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Tata B, Mimouni NEH, Barbotin AL, Malone SA, Loyens A, Pigny P, et al. Elevated prenatal anti-M\u00fcllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med. 2018;24:834-46.","DOI":"10.1038\/s41591-018-0035-5"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 2005;3:28.","DOI":"10.1186\/1477-7827-3-28"}],"container-title":["Journal of Turkish Society of Obstetric and Gynecology"],"original-title":[],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T10:44:26Z","timestamp":1734086666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tjoddergisi.org\/articles\/association-between-serum-copeptin-levels-and-non-obese-normoglycemic-polycystic-ovary-syndrome-a-case-control-study\/doi\/tjod.galenos.2024.65703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,12]]}},"URL":"https:\/\/doi.org\/10.4274\/tjod.galenos.2024.65703","relation":{},"ISSN":["1307-699X","2149-9330"],"issn-type":[{"type":"print","value":"1307-699X"},{"type":"electronic","value":"2149-9330"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}